

## PHARMANUTRA S.P.A. STRENGTHENS PRESENCE ON TAIWANESE MARKET

***The PharmaNutra Group expands its partnership with HONG CHI Biotech, which will include the new SiderAL® Drops P into its product portfolio after the success of SiderAL® Forte Int.***

Pisa, 13 January 2022 – [PharmaNutra S.p.A.](https://www.pharmanutra.it) (MTA; Ticket PHN), a group of companies specialised in mineral supplements and medical devices for muscles and joints, has signed a new distribution agreement with Taiwan's HONG CHI Biotech, a company in the KSMG group (Kuang Sheng Medical Group Pharma).

HONG CHI Biotech, which has distributed SiderAL® Forte Int. 30 tablets 30 mg Sucrosomial® Iron since 2019, signed the new agreement with Junia Pharma S.r.l. (a PharmaNutra S.p.A. subsidiary) for the commercialization of SiderAL® Drops P 7 mg Sucrosomial® Iron brand on the local market, thereby extending its range of Sucrosomial® Iron-based products to the paediatric sector. The new supplement will be distributed as soon as the product registration procedure has been completed.

*"We are pleased to consolidate our partnership with HONG CHI Biotech; the distribution of the new SiderAL® Drops P 7 mg broadens the Sucrosomial® Iron offer on the local market with a specific paediatric product", said Group Chairman Andrea Lacorte. "Furthermore, Taiwan is a very receptive and strategically important market in Southeast Asia; strengthening this partnership will guarantee significant new development prospects for both companies."*

### PharmaNutra S.p.A.

*Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology, and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies and parapharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.*

[PharmaNutra.it](https://www.pharmanutra.it)

*For further information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)